


IPW

Please Direct All Correspondence to Customer Number 45,311**TRANSMITTAL LETTER****INFORMATION DISCLOSURE STATEMENT**

Applicant : Jessouroun et al.

App. No : 10/566,898

Filed : February 1, 2006

For : PROCESS FOR PREPARING
POLYSACCHARIDE-PROTEIN
CONJUGATE VACCINES

Examiner : Unknown

Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 30, 2006

(Date)

Nancy W. Vensko, Reg. No. 36,298

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:

- (X) Listing 10 references.
- (X) Enclosing 9 references.

(X) Return prepaid postcard.


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580

PA-125

2865567:vr
082306

3

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Jessouroun et al.
App. No : 10/566,898
Filed : February 1, 2006
For : PROCESS FOR PREPARING
POLYSACCHARIDE-PROTEIN
CONJUGATE VACCINES
Examiner : Unknown
Art Unit : 1645

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 10 references to be considered by the Examiner. Also enclosed are 9 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note the relevance of the French-language reference (Mulard) is that it is cited in the International Search Report from PCT priority application serial no. PCT/US2004/026431.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/30/06

By: 

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>		Application No.	10/566,898
		Filing Date	February 1, 2006
		First Named Inventor	Jessouroun, Ellen
		Art. Unit	1645
SHEET 1 OF 1		Examiner	Unknown
		Attorney Docket No.	NIH275.001NP2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,356,170 A	10-26-1982	Jennings et al.	
	2	WO 2005/014037 A2, US 10/566,899 (National Phase of the above PCT application)	02-17-2005	The Government of the United States of America	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ¹
	3	BARTOLONI, A. et al. 1995 "Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide" <i>Vaccine</i> 13:463-470.					
	4	GUO, Z. and Jennings, H. 2001 "Protein-polysaccharide conjugation" In <i>Methods in Molecular Medicine, Meningococcal Vaccines: Methods and Protocols</i> , Eds. Pollard, A.J. and Maiden, M.C.J., Humana Press Inc., Totowa, N.J. 66:49-54.					
	5	JENNINGS, H. and Lugowski, C. 1981 "Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates" <i>J. Immunol.</i> 127:1011-1018					
	6	KONADU, E. et al. 2000 "Phase 1 and 2 studies of <i>Salmonella enterica</i> serovar <i>Paratyphi</i> A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam" <i>Infect. Immun.</i> 68:1529-1534.					
	7	LEE, C.-J. 2002 "Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry" <i>Biologicals</i> 30:97-103.					
	8	LEES, A. et al. 1996 "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents" <i>Vaccine</i> 14:190-198.					
	9	MULARD, L. et al. 2002 "Vaccins polyosidiques" <i>Ann. L'Institut Pasteur Act.</i> 12 :37-54.					
	10	SHAFFER, D. et al. 2000 "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides" <i>Vaccine</i> 18:1273-1281.					

2786447
072706

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

¹ - Place a check mark in this area when an English language Translation is attached.